BioLineRx Ltd..
BLRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
BioLineRx Ltd. is a biopharmaceutical company focused on developing and commercializing novel pharmaceutical products, primarily in the fields of oncology and immunology. The company's pipeline includes clinical-stage therapeutic candidates and collaborations with pharmaceutical companies. BioLineRx...Show More
Better Health for All
-20
BioLineRx's core product, Aphexda, received FDA approval for mobilizing hematopoietic stem cells in multiple myeloma patients, indicating a significant positive health impact.
1
The company's focus on oncology and immunology for unmet medical needs suggests its business strategy is centered on delivering significant health benefits. There is no evidence of revenue from products with negative health outcomes. However, the listed price for Aphexda is high, ranging from $5,900 to $6,623.29 per vial/dose.
2
While the company offers patient assistance programs, including BioLineRx Connect which allows underinsured/uninsured patients to pay as low as $0 per fill, and co-pay relief programs offering up to $7,500 in annual savings for Medicare/Medicaid patients, eligibility for these programs is restricted, for example, requiring patients to be between 400-500% of the Federal Poverty Level for one program.
3
This suggests that access for vulnerable populations is limited, with only a small percentage likely reached. The company provides pricing information and details on patient assistance programs, indicating good transparency regarding product access.
4
Aphexda has orphan drug designation, which typically grants market exclusivity and can restrict access to the drug through generic competition.
5
The company's website indicates that a page related to clinical trials is unavailable, suggesting a lack of transparency regarding clinical trial ethics.
6
Fair Money & Economic Opportunity
0
No evidence available to assess BioLineRx Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative evidence is available across the provided articles to assess BioLineRx's performance on any of the Fair Pay & Worker Respect KPIs. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not explicitly stated with the required data points.
1
Fair Trade & Ethical Sourcing
0
No relevant data was found in the provided articles to assess BioLineRx Ltd. against the 'Fair Trade & Ethical Sourcing' value. The articles explicitly stated that data extraction was prevented due to throttling, resulting in no specific facts or figures being available for any of the KPIs.
1
Honest & Fair Business
0
No evidence available to assess BioLineRx Ltd. on Honest & Fair Business.
Kind to Animals
-30
BioLineRx conducts pre-clinical studies on animals to assess the safety profile of its drugs, including GLIX1, BL-5040, and BL-1040, using various animal models.
1
This practice is a core part of their drug development. There is no mention of a policy prohibiting discretionary testing, nor any indication of alternative methods overriding legal mandates.
2
The company is a biopharmaceutical firm developing multiple drug candidates, which typically involves a volume of 7,000–10,000 animals annually for preclinical studies.
No War, No Weapons
0
No specific, concrete data points were found in the provided articles to assess BioLineRx Ltd. against the 'No War, No Weapons' ethical value. The articles either explicitly state that no sustainability data is available for BLRX.US
1
or the provided links were not found, preventing any analysis of relevant metrics such as revenue from arms contracts, dual-use technology, sales to embargoed regimes, or peacebuilding investments.
2
Planet-Friendly Business
0
No environmental, social, or governance (ESG) data related to planet-friendly business practices is available in the provided articles for BioLineRx Ltd.
1
The articles explicitly state that sustainability data is unavailable or that access to relevant content was throttled, preventing the extraction of any metrics for assessment.
2
Respect for Cultures & Communities
0
The provided articles focus on BioLineRx's financial performance, clinical trial updates, and internal company culture. There is no specific, concrete data available regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investment, grievance mechanisms, or any other metrics related to respect for cultures and communities.
1
Therefore, no KPIs under this value can be scored based on the evidence provided.
Safe & Smart Tech
0
The company's privacy policy, last updated in November 2023, states that users have rights to access, update, delete, restrict, and port their data, and to object to processing, with identity verification potentially required.
1
The policy also indicates that data is retained only as needed for business purposes or legal obligations.
2
Additionally, it mentions compliance with applicable laws and regulations, including those related to data protection.
3
Zero Waste & Sustainable Products
0
The provided article focuses on BioLineRx's drug development activities and does not contain any data relevant to waste management, sustainable products, or zero-waste initiatives.
1
Therefore, no specific evidence could be extracted to assess the company against the 'Zero Waste & Sustainable Products' value.
2